Recruiting
Phase 2

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Sponsor:

Alliance Foundation Trials, LLC.

Code:

NCT04335682

Conditions

Metastatic Prostate Cancer

Prostate Cancer Metastatic

Prostate Cancer

Castrate Resistant Prostate Cancer

Hormone Sensitive Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Darolutamide

Enzalutamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information